Status:

COMPLETED

Clinical Trial to Assess the Improvement of Fatigue, Sleep Problems, Anxiety / Depression, Neurovegetatives Alterations and Quality of Life After the Administration of ImmunoVita® in Chronic Fatigue Syndrome Patients

Lead Sponsor:

Vitae Health Innovation

Collaborating Sponsors:

Hospital Vall d'Hebron

Conditions:

Chronic Fatigue Syndrome

Myalgic Encephalomyelitis

Eligibility:

All Genders

18-65 years

Phase:

NA

Brief Summary

Chronic Fatigue Syndrome, also known as Myalgic Encephalomyelitis (CFS / MS) is a medical entity characterized mainly by debilitating and prolonged fatigue lasting more than 6 months, post-exertion fa...

Detailed Description

In patients with CFS / ME, neuroimmune, gastrointestinal, autonomic and cardiovascular alterations have been observed, among others. CFS / ME is characterized by disabling chronic fatigue, non-restora...

Eligibility Criteria

Inclusion

  • Adult patients of both sexes, between 18-65 years.
  • Patients with a BMI ≤ 25.
  • Patients diagnosed with Chronic Fatigue Syndrome according to diagnostic criteria of 1994 CDC / Fukuda and 2003 Canadian criteria from the University of Central Sensitization Syndrome (Vall d'Hebron University Hospital, Barcelona).
  • Patients who freely grant written consent.

Exclusion

  • Patients who are participating in another clinical trial of the same or different nature in the last 30 days prior to inclusion.
  • Any subject that, in the opinion of the investigator, is not able to follow the instructions or make a good completion of the treatment.
  • Subjects who do not grant written informed consent to participate in the study.
  • Patients who are receiving any of the prohibited drugs or products and that the withdrawal of the drugs / products not allowed in the study is expected to pose a relevant problem.
  • Pregnant women and / or during breastfeeding periods.
  • Patients under treatment with oral anticoagulants.
  • Patient with any type of immunosuppression.

Key Trial Info

Start Date :

November 10 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 31 2023

Estimated Enrollment :

67 Patients enrolled

Trial Details

Trial ID

NCT04301609

Start Date

November 10 2021

End Date

January 31 2023

Last Update

March 15 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Hospital Vall d'Hebron

Barcelona, Spain, 08035